Antherieu, Gabriel http://orcid.org/0000-0002-6043-2580
Heiblig, Maël
Freyer, Gilles
Ghesquieres, Hervé
Falandry, Claire
Article History
Accepted: 13 March 2023
First Online: 20 April 2023
Declarations
:
: No external funding was used in the preparation of this manuscript.
: Claire Falandry reported personal fees from Leo Pharma, Pfizer, MSD Oncology, Teva, AstraZeneca, Baxter, Eisai, Janssen Oncology, Novartis, Chugai Pharma and Astellas Pharma outside the submitted work; grants from Chugai Pharma, Pfizer, Pierre Fabre and Astellas Pharma outside the submitted work; and non-financial support from Janssen Oncology, Pierre Fabre, AstraZeneca and Leo Pharma outside the submitted work. Gabriel Antherieu, Maël Heiblig, Hervé Ghesquieres, and Gilles Freyer declare they have no conflicts of interest that might be relevant to the contents of this manuscript.
: All patients included in this study provided informed consent regarding data collection and publication of the corresponding results. This study was approved by the Scientific and Ethical Committee of Hospices Civils de Lyon (N° 22-5014) and was registered in accordance with local guidelines.
: The datasets generated during and/or analyzed during the current study are not publicly available due to ethical and privacy reasons but are available from the corresponding author on reasonable request.
: Conceptualization: GA, CF, MH. Methodology: GA, CF, MH. Validation: GA, CF, MH. Formal analysis: GA, CF. Investigation: GA, CF. Resources: CF. Data curation: GA, CF. Writing—original draft preparation: GA, CF. Writing—review and editing: GA, CF, GF, HG, MH. Supervision: CF, MH. Project administration: GA, CF. Funding acquisition: Not applicable. All authors have read and agreed to the published version of this manuscript. Every person involved in this analysis was offered authorship.
Free to read: This content has been made available to all.